SCHEDULE 13G: BlackRock Discloses 5.2% Stake in Candel Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Candel Therapeutics Inc. common stock as of December 31, 2025.
Summary
- BlackRock, Inc. beneficially owns 2,859,610 shares of Candel Therapeutics Inc. common stock.
- This ownership represents 5.2% of the total outstanding common stock of Candel Therapeutics Inc.
- BlackRock, Inc. holds sole voting power over 2,821,816 shares.
- BlackRock, Inc. holds sole dispositive power over 2,859,610 shares.
- No shared voting or dispositive power is reported.
- The filing was made by BlackRock, Inc. as a parent holding company, with several BlackRock subsidiaries identified as entities that may beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant institutional ownership stake, which can be viewed as a vote of confidence, but contains no operational or financial performance data for the issuer.
Positives
- A significant institutional investor like BlackRock, Inc. holding a 5.2% stake can be interpreted as a positive signal of confidence in Candel Therapeutics Inc.'s long-term prospects.
Future Outlook
This filing is a disclosure of current ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or BlackRock's future investment intentions beyond the scope of regulatory compliance.
Industry Context
This filing indicates a routine institutional investment by BlackRock, one of the world's largest asset managers, in a biotechnology company. Such disclosures are common and reflect portfolio allocation decisions rather than specific strategic moves related to the issuer's operational performance.
Stakeholder Impact
- Shareholders: Increased institutional ownership by a prominent firm like BlackRock may signal confidence in the company, potentially attracting further investor interest and influencing stock price positively.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Execution date of the Power of Attorney document by BlackRock, Inc. |
| 2025-12-31 | Date of the event requiring the filing, reflecting BlackRock's beneficial ownership. |
| 2026-01-21 | Filing date of the Schedule 13G by BlackRock, Inc. |
Keywords
BlackRock, Candel Therapeutics, Institutional Ownership, Schedule 13G, Common Stock, Biotechnology, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.